NASDAQ:SCYX SCYNEXIS (SCYX) Stock Price, News & Analysis → Warning: this could blow your mind (From DTI) (Ad) Free SCYX Stock Alerts $1.47 +0.04 (+2.80%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$1.42▼$1.5250-Day Range$1.39▼$2.1452-Week Range$1.35▼$3.87Volume184,056 shsAverage Volume196,632 shsMarket Capitalization$54.70 millionP/E Ratio1.04Dividend YieldN/APrice Target$12.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get SCYNEXIS alerts: Email Address SCYNEXIS MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside733.3% Upside$12.25 Price TargetShort InterestHealthy2.54% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.23Based on 2 Articles This WeekInsider TradingN/AProj. Earnings Growth-78.46%From $1.95 to $0.42 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.20 out of 5 starsMedical Sector350th out of 938 stocksPharmaceutical Preparations Industry156th out of 433 stocks 3.5 Analyst's Opinion Consensus RatingSCYNEXIS has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.25, SCYNEXIS has a forecasted upside of 733.3% from its current price of $1.47.Amount of Analyst CoverageSCYNEXIS has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.54% of the outstanding shares of SCYNEXIS have been sold short.Short Interest Ratio / Days to CoverSCYNEXIS has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in SCYNEXIS has recently decreased by 9.09%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSCYNEXIS does not currently pay a dividend.Dividend GrowthSCYNEXIS does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SCYX. Previous Next 3.5 News and Social Media Coverage News SentimentSCYNEXIS has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for SCYNEXIS this week, compared to 2 articles on an average week.Search Interest4 people have searched for SCYX on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows5 people have added SCYNEXIS to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SCYNEXIS insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.40% of the stock of SCYNEXIS is held by insiders.Percentage Held by Institutions54.37% of the stock of SCYNEXIS is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for SCYNEXIS are expected to decrease by -78.46% in the coming year, from $1.95 to $0.42 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SCYNEXIS is 1.04, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 141.11.Price to Earnings Ratio vs. SectorThe P/E ratio of SCYNEXIS is 1.04, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 212.34.Price to Book Value per Share RatioSCYNEXIS has a P/B Ratio of 14.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insiders ExposedThis consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here. About SCYNEXIS Stock (NASDAQ:SCYX)SCYNEXIS, Inc., a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of various fungal infections, including invasive candidiasis, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.Read More SCYX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SCYX Stock News HeadlinesMarch 28, 2024 | globenewswire.comSCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 26, 2024 | americanbankingnews.comSCYNEXIS (NASDAQ:SCYX) Stock Passes Below Fifty Day Moving Average of $1.74March 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…March 19, 2024 | americanbankingnews.comSCYNEXIS (NASDAQ:SCYX) Downgraded by StockNews.com to "Hold"February 21, 2024 | benzinga.comSCYNEXIS Stock (NASDAQ:SCYX) Insider TradesFebruary 1, 2024 | markets.businessinsider.comPromising Antifungal Drug Developments Bolster Buy Rating for SCYNEXISJanuary 30, 2024 | finance.yahoo.comSCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology ConferenceJanuary 30, 2024 | finance.yahoo.comSCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis ConferenceMarch 28, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionJanuary 8, 2024 | stockhouse.comDEADLINE TODAY: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the FirmJanuary 6, 2024 | markets.businessinsider.comScynexis 48 Hour Deadline AlertJanuary 5, 2024 | finance.yahoo.comSCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, ItalyJanuary 1, 2024 | markets.businessinsider.comSCYX DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important January 8 Deadline in Securities Class Action - SCYXDecember 29, 2023 | stockhouse.comINVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the FirmDecember 29, 2023 | barrons.comFINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with to Contact the FirmDecember 26, 2023 | stockhouse.comScynexis Deadline ReminderDecember 25, 2023 | markets.businessinsider.comTOP RANKED ROSEN LAW FIRM Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYXDecember 23, 2023 | stockhouse.comSCYNEXIS, Inc. (SCYX) Securities Fraud: Contact Berger Montague To Discuss Your RightsDecember 22, 2023 | morningstar.comSCYNEXIS Inc SCYXDecember 21, 2023 | stockhouse.comDEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the FirmDecember 18, 2023 | markets.businessinsider.comSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of SCYNEXIS, Inc. (SCYX)December 17, 2023 | stockhouse.comSHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the FirmDecember 17, 2023 | markets.businessinsider.comROSEN, GLOBAL INVESTOR COUNSEL, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYXDecember 16, 2023 | barrons.comSCYX STOCK ALERT: Robbins LLP Reminds Investors of the Upcoming Lead Plaintiff Deadline in the Class Action Against Scynexis, Inc.December 12, 2023 | stockhouse.comDEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the FirmDecember 11, 2023 | markets.businessinsider.comROSEN, LEADING TRIAL ATTORNEYS, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYXDecember 5, 2023 | stockhouse.comROSEN, A LEADING LAW FIRM, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYXSee More Headlines Receive SCYX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SCYNEXIS and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today3/28/2024Next Earnings (Estimated)3/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SCYX CUSIPN/A CIK1178253 Webwww.scynexis.com Phone(201) 884-5485Fax201-884-5490Employees36Year FoundedN/APrice Target and Rating Average Stock Price Target$12.25 High Stock Price Target$15.00 Low Stock Price Target$9.00 Potential Upside/Downside+759.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$1.42 Trailing P/E Ratio1.00 Forward P/E Ratio0.73 P/E GrowthN/ANet Income$-62,810,000.00 Net Margins53.14% Pretax Margin53.14% Return on Equity238.09% Return on Assets81.71% Debt Debt-to-Equity Ratio0.13 Current Ratio7.66 Quick Ratio6.88 Sales & Book Value Annual Sales$5.09 million Price / Sales10.42 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book14.25Miscellaneous Outstanding Shares37,210,000Free Float35,571,000Market Cap$53.02 million OptionableOptionable Beta1.59 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. David Gonzalez Angulo M.D. (Age 59)CEO, President & Director Comp: $631.69kMr. Scott Sukenick J.D. (Age 46)Chief Legal Officer & Corporate Secretary Comp: $542.05kMr. Ivor Macleod CPA (Age 63)M.B.A., Chief Financial Officer Debbie EtchisonExecutive Director of CommunicationsMs. Daniella GiganteVice President of Human Resources & Information TechnologyKey CompetitorsEledon PharmaceuticalsNASDAQ:ELDNUnicycive TherapeuticsNASDAQ:UNCYAadi BioscienceNASDAQ:AADIDaré BioscienceNASDAQ:DAREHomology MedicinesNASDAQ:FIXXView All CompetitorsInstitutional OwnershipKingdon Capital Management L.L.C.Bought 359,900 shares on 3/18/2024Ownership: 6.012%Vanguard Group Inc.Bought 70,085 shares on 3/11/2024Ownership: 4.189%GSA Capital Partners LLPBought 19,663 shares on 2/16/2024Ownership: 0.100%Vanguard Group Inc.Bought 70,085 shares on 2/15/2024Ownership: 4.188%Citadel Advisors LLCSold 9,500 shares on 2/15/2024Ownership: 0.000%View All Institutional Transactions SCYX Stock Analysis - Frequently Asked Questions Should I buy or sell SCYNEXIS stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SCYX shares. View SCYX analyst ratings or view top-rated stocks. What is SCYNEXIS's stock price target for 2024? 3 brokers have issued 1 year target prices for SCYNEXIS's shares. Their SCYX share price targets range from $9.00 to $15.00. On average, they predict the company's stock price to reach $12.25 in the next twelve months. This suggests a possible upside of 733.3% from the stock's current price. View analysts price targets for SCYX or view top-rated stocks among Wall Street analysts. How have SCYX shares performed in 2024? SCYNEXIS's stock was trading at $2.23 on January 1st, 2024. Since then, SCYX stock has decreased by 34.1% and is now trading at $1.47. View the best growth stocks for 2024 here. When is SCYNEXIS's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024. View our SCYX earnings forecast. How were SCYNEXIS's earnings last quarter? SCYNEXIS, Inc. (NASDAQ:SCYX) released its earnings results on Wednesday, November, 10th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.73. The firm had revenue of $0.52 million for the quarter, compared to analyst estimates of $0.50 million. SCYNEXIS had a net margin of 53.14% and a trailing twelve-month return on equity of 238.09%. During the same quarter last year, the business posted ($0.28) EPS. When did SCYNEXIS's stock split? SCYNEXIS's stock reverse split on the morning of Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 16th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of SCYNEXIS own? Based on aggregate information from My MarketBeat watchlists, some companies that other SCYNEXIS investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Sorrento Therapeutics (SRNE), Gran Tierra Energy (GTE), KushCo (KSHB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Outlook Therapeutics (OTLK), Cogent Biosciences (UMRX) and Aeterna Zentaris (AEZS). Who are SCYNEXIS's major shareholders? SCYNEXIS's stock is owned by a variety of institutional and retail investors. Top institutional investors include Kingdon Capital Management L.L.C. (6.01%), Vanguard Group Inc. (4.19%), Vanguard Group Inc. (4.19%), Avidity Partners Management LP (3.89%), Stonepine Capital Management LLC (3.64%) and Decheng Capital LLC (1.49%). Insiders that own company stock include Marco Taglietti and Scott Sukenick. View institutional ownership trends. How do I buy shares of SCYNEXIS? Shares of SCYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SCYX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SCYNEXIS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.